Idera Pharmaceuticals Email Format
Biotechnology ResearchNorth Carolina, United States11-50 Employees
Idera Pharmaceuticals merged with Aceragen, Inc., a rare disease biopharmaceutical company, in September 2022. Aceragen subsequently began its wind-down in mid-2023.